Introduction. Medical treatment of women with idiopathic recurrent pregnancy loss is controversial. The objective was to assess the effects of different treatments on live birth rates and complications in women with unexplained recurrent pregnancy loss. Material and methods. We searched MEDLINE, Embase and the Cochrane Library, and identified 1415 publications. This systematic review included 21 randomized controlled trials regarding acetylsalicylic acid, low-molecular-weight heparin, progesterone, intravenous immunoglobulin or leukocyte immune therapy in women with three or more consecutive miscarriages of unknown cause. The study quality was assessed and data was extracted independently by at least two authors. Results. No significant difference in live birth rate was found when acetylsalicylic acid was compared with low-molecular-weight heparin or with placebo. Meta-analyses of low-molecular-weight heparin vs. control found no significant differences in live birth rate [risk ratio (RR) 1.47, 95% CI 0.83-2.61]. Treatment with progesterone starting in the luteal phase seemed effective in increasing live birth rate (RR 1.18, 95% CI 1.09-1.27) but not when started after conception. Intravenous immunoglobulin showed no effect on live birth rate compared with placebo (RR 1.07, 95% CI 0.91-1.26). Paternal immunization compared with autologous immunization showed a significant difference in outcome (RR 1.8, 95% CI 1.34-2.41), although the studies were small and at high risk of bias. Conclusion. The literature does not allow advice on any specific treatment for idiopathic recurrent pregnancy loss, with the exception of progesterone starting from ovulation. We suggest that any treatment for recurrent pregnancy loss should be used within the context of a randomized controlled trial.
Introduction
Recurrent pregnancy loss (RPL) is a condition causing much anxiety and worry for the couples involved (1) (2) (3) . In about half of the cases, RPL is unexplained, i.e. idiopathic RPL (4) . There is no evidence-based treatment for these women (5-8) but several suggestions for treatments such as acetylsalicylic acid (ASA), low-molecularweight heparin (LMWH), progesterone, intravenous immunoglobulin (IvIg), corticosteroids, leukocyte immune therapy (LIT), pre-implantation genetic screening (PGS) and tender loving care (TLC) have been put forward (6, (9) (10) (11) .
Studies on the topic are difficult to compare, mainly due to a lack of consensus on the definition of RPL (12, 13) . The most appropriate definition of RPL is three or more consecutive miscarriages before gestational week 22 (gestational age 21 weeks +6 days) (5, 10, 11, 14, 15) . According to this, the incidence of RPL is estimated to vary between 0.5 and 2.3% in different populations (12, 14, (16) (17) (18) (19) . However, some define RPL as two or more miscarriages (15) . Besides the spread of many definitions, the uncertainty regarding RPL incidence is also due to the unknown number of unreported miscarriages (5, 6, 13, 20) .
RPL is associated with certain conditions or the presence of risk factors, such as increased maternal age, number of previous miscarriages, maternal distress, lifestyle factors, thyroid dysfunction and uterine anomalies (9, 12, 16, 21, 22) . Other known risk factors are maternal antiphospholipid antibodies, hereditary thrombophilia and the presence of parental chromosomal abnormalities (9, 12, 21, 23) . Despite thorough evaluation to identify presumptive risk factors and pathophysiologic mechanisms, we are often left without a target towards which we can direct a specific therapy or prophylaxis. Hence, the RPL patients are often exposed to treatments based on theoretical hypotheses without proven efficacy (24) .
The primary aim of this systematic review was to compare the efficacy of medical treatment for women with idiopathic RPL. The primary outcome was live birth after the 22nd gestational week and secondary outcomes were complications/side effects of the intervention. Treatments with ASA, LMWH, progesterone, corticosteroids, IvIg, LIT, lipid emulsion, TLC and PGS were evaluated.
Material and methods
This review was conducted according to PRISMA guidelines for systematic reviews and the PRISMA checklist was completed (25) . The Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria were followed to assess the certainty of evidence across the selected studies (26) .
Sources
To identify relevant literature we searched the following electronic databases: MEDLINE PubMed, EMBASE, and Cochrane Library.
The search string included synonyms for RPL and different treatments. The search terms were established with professional help from a librarian at Lund University. Search terms were: "recurrent miscarriage", "recurrent spontaneous abortion", "recurrent pregnancy loss", "habitual abortion", therapy. The search-line for therapy was: "LIT", "leukocyte immunotherapy", "paternal lymphocyte immunization", "third party donor", "preimplantation genetic screening", "heparin", "low-molecular-weight heparin", "lipid emulsion", "progesterone", "acetylsalicylic acid", "psychological support", "tender loving care", "supportive care", "emotional support", "intravenous immunoglobulin", and "corticosteroids".
Filters were; Human, English, Norwegian, Swedish, Danish languages. We set no time limit for first publication. The last search was conducted on 13 September 2017. The reference lists of the identified reports including relevant reviews were manually searched for other relevant additional publications. The focused research questions were as shown in PICO (Table 1) .
Study selection and data extraction
Inclusion criterion was study populations of women with idiopathic RPL, defined as at least three consecutive miscarriages. The assessments performed to define women with idiopathic RPL are presented in Supporting Information Table S1 . In the final assessment we only included randomized control trials (RCTs) in order to achieve the highest level of certainty for the evidence. Only studies with the outcome of live birth and/or complication were included.
Exclusion criteria were: articles regarding specific diagnosis-related treatment, studies with two recurrent
Key message
High quality evidence for medical treatment of women with idiopathic recurrent pregnancy loss started after conception is lacking. Progesterone started in the luteal phase may be effective in improving the live birth rate. Any other treatment should be used within a randomized controlled trial. miscarriages as the definition of RPL, known cause of RPL, pregnancies after in vitro fertilization (IVF), animal and biochemical studies, articles not addressing the subject, articles without patient data and systematic reviews, cohort studies, and case series.
A first selection was made from titles and abstract. Two authors independently identified trials fulfilling the PICO criteria for inclusion, assessed risk of bias, and extracted data from all included trials (27) . Data was extracted regarding author, year of publication, location, study design, study duration, number of participants, type of intervention and control group, mean age and outcome data.
Outcomes
Live birth at gestational age ≥22 completed weeks or complications or side effects.
Risk of bias
For assessing risk of bias within individual studies, the included articles were evaluated using validated checklists for RCTs from The Swedish Agency for Health Technology Assessment (HTA) and Assessment of Social Services (SBU) and modified by the HTA-centrum. The appraisal addressed directness (external validity), risk of bias (internal validity) and precision. All three domains are presented in three levels ( Table 2) .
The certainty of evidence across studies was assessed by all authors and rated for all outcomes separately using the GRADE approach. Any disagreement concerning data or quality assessment was discussed within the entire author group until consensus was reached.
Statistical analyses
When possible, extracted data was pooled in meta-analyses, using REVIEW MANAGER 5.3. A random-effects model was applied. The effect estimate was expressed as a risk ratio (RR) with 95% confidence interval (CI). The individual studies and the pooled estimates were presented graphically by forest plots. Statistical heterogeneity was examined using the Chi-square test and the I 2 -characteristics. Clinical sources of heterogeneity were explored by stratified analyses.
Result

Search results
The search identified 1415 publications with 102 duplicates. After the exclusion of 1187 articles based on title and abstract, 126 full-articles were reviewed. Another 105 were excluded because they were duplicate publications or non-randomized clinical trials, included known etiology or were not relevant for this review. Finally, 21 RCTs were included. The PRISMA flow chart illustrates the selection process (Figure 1 ).
Included trials
Included articles and their characteristics are presented in Table 3 . All 21 RCTs reported live birth rates. Seventeen studies reported on adverse events or pregnancy, obstetric and neonatal complications. Study characteristics and the quality assessment for the two outcomes live birth and complications are presented in Tables 4 and 5 , respectively. No RCTs on lipid emulsion, corticosteroids, TLC and PGS were found.
Live birth
Acetylsalicylic acid. Two small RCTs with high risk of bias reported live birth rates (28, 29) . One study (29) compared ASA with LMWH and found no significant difference (84 vs. 82%; RR 0.92, 95% CI 0.58-1.46) ( Table 4 ). In the other study (28) , ASA (n = 27) was compared with placebo (n = 27) and live birth rates were 81% for both groups. There was insufficient data for any conclusions about the effect of this treatment. The certainty of evidence was very low (GRADE ⊕◯◯◯).
Low-molecular-weight heparin. Four RCTs were included with different controls. None of the studies (31) , whereas the controls in the two remaining studies received placebo (32, 33) . Meta-analyses of three studies with controls without active treatment found no significant difference in live birth rate with estimated RR of 1.47 (95% CI 0.83-2.61) (Figure 2 ). Possible clinical sources to explain the high heterogeneity were dose and gestational age at the start of treatment,
although not confirmed at stratified analyses, possibly due to too few studies. Three of four studies were at high risk of bias. The certainty of evidence was low (GRADE ⊕⊕◯◯).
Progesterone. Dydrogesterone showed a positive effect on live birth in two studies (Table 4 ) (34, 35) . However, the studies were small and had an unclear risk of bias. The results were not pooled in a meta-analysis, as different control groups were used and one of the trials did not have a placebo group. A large RCT (n = 836) compared vaginal progesterone with placebo (36) . Treatment was started at the time of verified pregnancy and up to six weeks of gestation. Live birth rates were similar in the two groups (65.8 vs. 63.3%; RR 1.04, 95% CI 0.94-1.15). The study concluded that there was no effect of progesterone during the first trimester when started after implantation. Another large RCT (n = 700) started treatment with vaginal progesterone or placebo at ovulation, continuing through the luteal phase and confirmation of conception (37) . Live birth rate was higher during active treatment (92%) than placebo (77%) ( Table 4 ). The main difference in design between these two RCTs was when treatment was initiated. The results of the progesterone studies are depicted in Figure 3 . No summary estimate was calculated, due to the different starting points. Potential clinical sources of heterogeneity were dose, gestational age at start and length of treatment. There were too few studies to draw firm conclusions from stratified analyses.
The certainty of evidence was moderate (GRADE ⊕⊕⊕◯).
Corticosteroids. No RCT on prednisolone treatment was found.
Intravenous immunoglobulin. Six RCTs (controls given albumin, saline, LMWH+ASA or placebo) were included (Table 4) (38) (39) (40) (41) (42) (43) . No individual study or the pooled data from the meta-analysis showed any beneficial effect. The meta-analysis of five studies showed no significant effect on live birth rate (RR 1.07, 95% CI 0.91-1.26) when IvIg was compared with placebo or other treatment ( Figure 4 ). The certainty of evidence was very low (GRADE ⊕◯◯◯).
Leukocyte immunization. Five RCTs were included (44) (45) (46) (47) . The meta-analysis on four studies where the intervention with paternal immunization was compared with autologous immunization, found a significant difference in live birth rate (73 vs. 41%; RR 1.8, 95% CI 1.34-2.41) ( Figure 5 ).LIT treatment was abandoned many years ago. These studies, even though they are small, give the impression that paternal immunization is effective. The effect is probably overestimated due to an exceptionally low pregnancy rate in the control groups. The certainty of evidence was very low (GRADE ⊕◯◯◯).
Lipid emulsion. No RCT regarding this treatment was found.
Tender loving care. No RCT regarding this treatment was found.
Pre-implantational genetic screening. No RCT regarding this treatment was found.
Side effects
There were no reported complications of ASA in the two included studies. Trials studying LMWH reported expected complications such as local skin reactions and small bleeding. No complications of progesterone treatment were reported. Headache, itching, flushing and fever were associated with IvIg and were reported in most of the studies with this intervention. Adverse effects were sparsely or not reported in the studies on leukocyte immunization (Table 5 ). Comparison using statistical analyses was not feasible due to heterogeneous reporting of complications.
Discussion
We included 21 studies assessing the effect of ASA, LMWH, progesterone, IvIg or LIT in women with three or more recurrent miscarriages with unknown etiology. RCTs were not found concerning treatment with prednisolone, lipid emulsion, PGS and TLC. The present systematic review has identified knowledge gaps in the area of treatment of RPL. There is no high quality evidence to support any form of medical treatment to improve the outcome of live birth. Still, these women must be taken care of according to present knowledge despite the low certainty of evidence. Our systematic review has several strengths. We followed the PRISMA guidelines (25) for Systematic Reviews and completed the PRISMA checklist. We conducted an extensive literature search with several updates to include all relevant studies fulfilling our PICO (Table 1 ). In the inclusion and exclusion process we thoroughly followed our predefined participants, interventions, comparisons and outcomes to avoid bias in the review process. In order to achieve the highest quality of evidence, this review included only RCTs. We assessed the certainty of evidence across studies with the GRADE system (26). Stephenson ( Only pregnancy loss is stated in the study and no clear number of live birth rate, although pregnancy outcome (abruption, pre-eclampsia etc.) are stated. The data of live birth are extracted from the total numbers of pregnancies subtracted with the presented pregnancy losses. Study stopped at interim analysis since it was estimated that the study could not meet the criteria for statistical significance based on the power calculation. Table 5 . When including trials, we adhered strictly to the definition of at least three consecutive miscarriages. Several RCTs with large sample sizes were therefore excluded. The inclusion of such trials might have altered the results. Although women with only two miscarriages have a better pregnancy prognosis than women with three or more miscarriages (48) , the relative effect of treatments might not have differed.
Our findings and interpretations suffer from the low quality in most of the randomized trials included in the review. The risk of bias assessment revealed a high risk of bias in many studies. The reporting of complications was heterogeneous and sometimes missing, and it was not possible to pool the results. Both meta-analyses involving LMWH and progesterone expressed high heterogeneity. Potential explanations are the differences in doses, when treatment was started and finished, as well as the risk of bias. Stratified analyses could neither confirm nor rule out any of those potential explanations as a source of heterogeneity, mainly due to the low number of studies.
Acetylsalicylic acid: Low-dose aspirin is an antiplatelet agent which irreversibly inhibits platelet cyclo-oxgenase and thereby decreases the production of thromboxane A2 (TXA2), a potent vasoconstrictor and platelet activator (28) . The hypothesis of an impaired placental circulation due to microthrombosis as a cause of RPL (29,49) is the background for treatment with ASA (50).
The two RCTs comparing ASA with placebo and LMWH, respectively (28, 29) , did not find a significant difference in live birth rate. Problems with applicability, precision and risk of bias decreased the certainty of evidence.
Many RCTs investigating the effect of ASA included women with two or more miscarriages and with or without antiphospholipid syndrome (APS) (51) (52) (53) (54) (55) . In most trials, ASA is given in combination with another drug, usually LMWH (30, 53) . A meta-analysis (56) with 16 included studies showed that ASA combined with LMWH therapy improved the live birth rate compared with ASA mono-therapy (RR 1.18, 95% CI 1.06-1.31). Many of the included studies in that review did not fulfill our PICO and are therefore not reported in this review. Tong (57) concluded that their meta-analysis did not provide evidence that aspirin-heparin therapy had a beneficial effect on unexplained recurrent miscarriage in terms of live birth rate. In the ALIFE trial (53) , neither aspirin combined with LMWH nor aspirin alone improved the chance of a live birth in women with a history of at least two unexplained miscarriages.
Low-molecular-weight heparin: Prophylactic use of anticoagulants such as LMWH, is based on the Only those who gave birth were followed up for adverse events.
ASA, acetylsalicylic acid; DVT, deep vein thrombosis; hCG, human chorionic gonadotropin; IUFD, intrauterine fetal death; IUGR, intrauterine growth restriction; LMWH, low-molecular-weight heparin; RCT, randomized controlled trial. immunopathological evaluations showing concomitant inflammation and thromboembolism in the placenta and the decidua (24) . LMWH has been shown to have potentially beneficial effects on trophoblast implantation and to influence trophoblast apoptosis. LMWH inhibits factor Xa more effectively than factor IIa to produce its antithrombotic effect. LMWH does not cross the placenta and is safe for the fetus (31). Shaaban (33) found a significant difference in live birth rate in favor of LMWH compared with placebo. There was a surprisingly high fetal death rate after 20 gestational weeks in both the intervention and the control groups (13.7 vs. 27.5%). The live birth rate for the control group was unexpectedly low (32%). Fawzy (30) also found a significantly higher live birth in the intervention group vs. placebo, despite the small sample sizes (60 vs. 50) . The live birth rate in the control group was also very low (48%). A larger RCT (32) with about 170 women in each arm did not find a significant difference in the live birth rates. When the studies were pooled in a meta-analysis no convincing effect on pregnancy outcome was revealed. Problems with applicability, precision and risk of bias resulted in low certainty of evidence for treatment with LMWH. LMWH probably has no effect on the chance of live birth with placebo/no treatment.
Pasquier and Schleussner (58, 59) found that LMWH did not improve the chance of a live birth in women with unexplained recurrent miscarriage. The combination treatment LMWH and ASA, in the SPIN intervention trial (52), supported the above findings. However, these trials included women with only two or more miscarriages.
A systematic review (60) included nine rather heterogeneous studies of varying quality, with only two miscarriages as inclusion criteria. No beneficial effect of anticoagulants (LMWH and ASA) in studies at low risk of bias was found. No other systematic reviews with our inclusion criteria with three or more consecutive miscarriages were found.
Progesterone: Progesterone, secreted by the corpus luteum and the placenta, has a central role in maintaining a pregnancy (36) . Progesterone deficiency may be associated with insufficient endometrial maturation and inadequate regulation of inflammatory mediators. Supplementation with progesterone is thought to establish an immune response inducing a pregnancy-protective shift from pro-inflammatory Th-1 cytokine responses to a more favorable anti-inflammatory Th-2 cytokine response. Support with progesterone may therefore theoretically help to prevent pregnancy loss (37) .
Only one (37) of the four studies (34-37) included in this review showed a positive effect of progesterone treatment on live birth rate in women with RPL. This study started treatment in the luteal phase, which seems to be important for efficacy. It is a strong recommendation not to treat this patient group with progesterone after implantation but it can be considered if started at ovulation and during the luteal phase.
In Haas' systematic review on progesterone in women with RPL, no evidence that progesterone can prevent miscarriage was found. Only two of the 14 studies enrolled women with three or more miscarriages. A sub-group analysis of these studies showed a significant difference in reduction of miscarriage in favor of those who were treated with progesterone compared with no treatment. However, these trials were of poor methodological quality, so these findings should be interpreted with caution (61) .
IvIg: Immunological disturbances are hypothesized to play an important role in RPL and therefore IvIg, as an inhibitor of the immune system, has been tested in RPL patients. IvIg has several effects such as suppression and neutralization of autoantibodies, attenuation of natural killer cells, inhibition of complement binding, modification of cytokine production, and expansion of regulatory T lymphocytes (62) .
Based on our results we conclude that there is low certainty of evidence to recommend IvIg to patients with RPL. Several studies were small and some were not completed. The effect of this treatment cannot be evaluated based upon the low quality of the present studies. More randomized controlled studies are required to justify the use of IvIg in patients with recurrent miscarriages.
In a systematic review, Hutton found no significant increase in the odds ratio (OR) of live birth when women with RPL were treated with IvIg compared with placebo (OR 1.28, 95% CI 0.78-2.10). There was, however, a significant increase in live births following IvIg use in women with secondary recurrent miscarriage (OR 2.71, 95% CI 1.09-6.73). This review included two studies which our review had excluded because of their enrollment of women with two miscarriages and known etiology of RPL (63) . Neither Egerup nor Ata found an improved live birth rate after treatment with IvIg, according to meta-analyses of 11 and six studies, respectively. The reviews included studies with two miscarriages and the study by Egerup also included APS as a known cause of RPL (62, 64) .
LIT: The theory behind using LIT was that women with RPL lack anti-paternal antibodies or blocking antibodies that protect the fetus against rejection, and the subsequent production of these antibodies after LIT was suggested to be beneficial (65) .
In our review it is uncertain if leukocyte immunization affects the chance of live birth because of the low study quality, low number of patients, and lack of consistency in patients recruited.
A meta-analysis on allogenic LIT by Liu et al. Tender loving care: No RCTs were found on TLC and the observational studies have small sample sizes. Although the quality of evidence is low for treatment with psychological support to improve the live birth rate in a subsequent pregnancy in women with unknown RPL, it is hard to argue against such treatment. The Royal College of Obstetricians and Gynecologists (RCOG) state, in their guideline from 2011, that patients with idiopathic recurrent miscarriages have a very good prognosis without medical treatment (11) . They recommend using TLC in a special clinic.
Several non-randomized studies reported that psychological support in early pregnancy decreases miscarriage rates in women with unexplained RPL. As early as 1954, Javert studied the need for psychotherapy for patients with recurrent miscarriage and estimated an increase in the live birth rate from 8.6 to 87.3% and a decrease in the abortion rate from 95 to 11.9% after psychotherapy (68) . Stray-Pedersen studied 195 couples with at least three consecutive miscarriages of unknown cause where 44% had no known etiology of RPL. Women receiving specific antenatal counseling and psychological support had a live birth success rate of 32/37 (86%), compared with 8/24 (33%) in women given no specific antenatal care (69). Clifford found that supportive care in early pregnancy conferred a significant beneficial effect on pregnancy outcome, with those who attended the early pregnancy clinic having a 26% (42/160) miscarriage rate in the next pregnancy compared with 51% (21/41) for those who did not attend the clinic (70) . Liddell et al. also showed a better success rate in live birth in women with unknown RPL who attended an early pregnancy clinic (86%) compared with women who attended their own practitioner and did not receive formal supporting care (33%).
Musters conducted a questionnaire study with 174 women with at least two miscarriages about their wishes regarding the next pregnancy. They wanted a plan for the first trimester including one doctor, ultrasounds, understanding and listening, awareness of obstetrical history and respect towards the patient and their miscarriage by the healthcare professionals (71) .
Side effects: Generally, side effects to the given treatments are well reported in most included studies and give the impression that they seem safe to use in a pregnant, high-risk population, for both the mother and the fetus. The majority of the adverse effects are best characterized as events without consequences. The adverse effects are also well known minor complications of the respective treatments, such as bruising on the injection site of LMWH, headache, itching, and fever associated with IvIg and face flushing, insomnia, and anxiety about using corticosteroids. The presence of obstetric complications did not differ between the index groups and controls. None of the studies reported serious adverse effects as a consequence of the treatment.
Conclusion
Present knowledge from the literature is insufficient to advise on any specific treatment for idiopathic RPL starting after conception. The only treatment that can be considered is progesterone initiated at ovulation and continuing through the luteal phase. We suggest that any other treatment for RPL should be used within the context of an RCT.
Supporting information
Additional supporting information may be found online in the Supporting Information section at the end of the article: Table S1 . Assessment to define idiopathic recurrent pregnancy loss.
